Akari Therapeutics grants director stock and options
The RSU awards were granted in lieu of accrued but unpaid cash retainers, with shareholder approval governing their vesting.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Akari Therapeutics Plc (AKTX) director Raymond Prudo-Chlebosz was granted 9,072 American Depositary Shares (ADSs) representing restricted stock units on August 18, 2026, and 3,240 ADSs on October 5, 2026, in lieu of accrued but unpaid cash retainers payable to non-executive directors. Both RSU awards are subject to forfeiture if shareholder approval of a proposed amendment increasing shares reserved under the equity incentive plan is not obtained, and vest in full on approval. He was also granted options for 30,000 ADSs and 15,000 ADSs on August 18, 2026, each with a $7.899 exercise price; vesting depends on approval and continued service.
Insider Trade Summary
Grant/Award: 57,312 shares
Grant/Award
4 txns
Insider
Prudo-Chlebosz Raymond
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | American Depositary Shares representing Ordinary Shares F2, F3 | 3,240 | $7.899 | $26K |
| Grant/Award | Stock Option (Right to Buy) F4 | 30,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F5 | 15,000 | $0.00 | $0.00 |
| Grant/Award | American Depositary Shares representing Ordinary Shares F1, F3 | 9,072 | $7.899 | $72K |
Holdings After Transaction:
Stock Option (Right to Buy) — 45,000 contracts (Direct);
American Depositary Shares representing Ordinary Shares — 76,861 shares (Direct)
Footnotes (5)
- F1. These American Depositary Shares ("ADSs") represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. This RSU grant was approved by the Board of Directors of the Issuer on August 18, 2026, and is subject to forfeiture if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan ("Shareholder Approval") is not obtained. The RSUs will vest in full on the date of Shareholder Approval.
- F2. These ADSs represent RSUs, with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. This RSU grant was approved by the Board of Directors of the Issuer on October 5, 2026, and is subject to forfeiture if Shareholder Approval is not obtained. The RSUs will vest in full on the date of Shareholder Approval.
- F3. This award of RSUs was granted in lieu of accrued but unpaid cash retainers payable to non-execute directors in accordance with the Issuer's remuneration policy.
- F4. On August 18, 2026, the Reporting Person was granted an option to purchase 30,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. The option will vest with respect to 4.17% for each one-month anniversary of August 18, 2026 that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the two-year anniversary of August 18, 2026, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
- F5. On August 18, 2026, the Reporting Person was granted an option to purchase 15,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. Beginning on the date of Shareholder Approval, this option will vest with respect to 8.33% of the grant on the date of Shareholder Approval plus 8.33% for each one-month anniversary of August 18, 2026 that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the one-year anniversary of August 18, 2026, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
Key Figures
ADSs representing RSUs: 9,072 ADSs
ADSs representing RSUs: 3,240 ADSs
Option grant: 30,000 ADSs
+3 more
6 metrics
ADSs representing RSUs
9,072 ADSs
Granted August 18, 2026
ADSs representing RSUs
3,240 ADSs
Granted October 5, 2026
Option grant
30,000 ADSs
Granted August 18, 2026
Option grant
15,000 ADSs
Granted August 18, 2026
Exercise price
$7.899 per ADS
Applies to both option grants
Ordinary shares per RSU
80,000 ordinary shares
Right to receive per RSU
Key Terms
restricted stock units, Shareholder Approval, equity incentive plan, vest in equal, monthly installments
4 terms
restricted stock units financial
"represent restricted stock units ("RSUs")"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
equity incentive plan financial
"shares reserved for issuance under the plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
vest in equal, monthly installments financial
"will vest in equal, monthly installments"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What awards did AKTX director Raymond Prudo-Chlebosz receive?
He received 9,072 ADSs representing RSUs on August 18, 2026, and 3,240 ADSs representing RSUs on October 5, 2026. He also received options for 30,000 ADSs and 15,000 ADSs on August 18, 2026, each with a $7.899 exercise price.
How do AKTX director Raymond Prudo-Chlebosz's options vest?
The 30,000-ADS option vests 4.17% for each monthly anniversary of August 18, 2026, elapsed before approval, with the remainder vesting monthly from the 18th of the month after approval through the two-year anniversary. The 15,000-ADS option vests 8.33% on approval plus 8.33% for each elapsed monthly anniversary, with the remainder vesting monthly through the one-year anniversary. Both schedules require continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
